Last reviewed · How we verify
NCT06358001
EchoTip AcuCore Post-Market Clinical Study
trial testing EchoTip AcuCore in Adenocarcinoma in 183 participants. Completed in 19 July 2025.
14 June 2025
Quick facts
| Lead sponsor | Cook Research Incorporated |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 183 |
| Start date | 5 August 2024 |
| Primary completion | 14 June 2025 |
| Estimated completion | 19 July 2025 |
| Sites | 8 locations across United States |
Drugs / interventions tested
- EchoTip AcuCore
Conditions studied
- Adenocarcinoma — all drugs for Adenocarcinoma →
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Sponsor
Cook Research Incorporated — full company profile →
Who can join
18 and older, any sex, with Adenocarcinoma or Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06358001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adenocarcinoma
Currently open trials in the same condition.
- NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
- NCT06649474 — Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels · NA · recruiting
- NCT05581121 — PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer · Phase 3 · recruiting
- NCT06128343 — Anatomical-Clinical Base of Adenocarcinoma Pancreatic · recruiting
- NCT05922930 — Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management · Phase 1, PHASE2 · recruiting
Other Cook Research Incorporated trials
Trials by the same sponsor.
- NCT06986954 — Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study · recruiting
- NCT06094127 — Zenith Thoracic Alpha (ZTA) Post-Market Data Collection · active not recruiting
- NCT05182255 — Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered · completed
- NCT04635228 — Biodesign® Otologic Repair Graft · completed
- NCT04987034 — Comparing a Direct Versus an Indirect Approach to Measuring the Portalsytemic Pressure Gradients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06358001 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cook Research Incorporated
- Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06358001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing